Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
List view / Grid view
Filter the results
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
Positive topline results have been announced from a Phase II trial of VENCLEXTA® (venetoclax) in combination with azacitidine in patients with acute myeloid leukaemia (AML).
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
Preliminary agenda and speakers announced for LogiPharma, The World’s Leading Pharma Supply Chain Event (21 – 23 April) 2020.
The CMA has cleared the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical company Roche Holdings.
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
Why has the pharma industry and its talents lost interest in developing new antibiotics?
This August saw nine new green lights from the FDA, all small molecules, which makes up a third of the approvals this year.